Desarrollo de Nanomateriales para una terapia avanzada en Esclerosis Lateral Amiotrófica
The DesvELA project focuses on creating new nanotechnology-based therapies for Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease with no cure and limited treatments. Using graphene quantum dots (GQDs) and mesoporous silica, the project aims to overcome the blood-brain barrier (BBB) to deliver ALS drugs (riluzole and edaravone) more effectively. GQDs and silica are optimized for drug delivery, co-functionalized with antioxidants and proteins to enhance treatment efficacy. The project will evaluate drug release, stability, antioxidant capacity, and BBB penetration, with potential applications for other neurodegenerative diseases.
